Senescent skin cells, often referred to as zombie cells because they have outlived their usefulness without ever quite dying, ...

Background Fibrolamellar carcinoma (FLC), a rare and fatal liver cancer lacking effective drug therapy, is driven by the DNAJ ...

Obe-cel is under regulatory review in both the EU and the U.K., and the Company expects to receive notification of approval status from the Medicines and Healthcare products Regulatory Agency (MHRA) ...

A common gastrointestinal cancer drug that crosses the blood-brain barrier showed promise in patients with aggressive ...

The White House Vets Pete Hegseth’s Replacement As U.S. Defense Secretary: Report ...

In a first-of-its-kind human trial, researchers transplanted iPS-cell-derived dopaminergic progenitors into patients with ...

In this week's Press Run there is news about John Carroll University's just-announced commencement speaker; an Olympic gold ...

Artiva Biotherapeutics, Inc.’s ARTV share price has dipped by 7.23%, which has investors questioning if this is right time to ...

The quest for more effective cancer radiotherapy continues apace, with Telix Pharmaceuticals (ASX:TLX) today reporting “encouraging” preliminary results from its phase II study to treat recurrent high ...

Subcutaneous Opdivo showed comparable effectiveness, safety and tolerability to IV Opdivo in advanced clear cell renal cell ...

Learn more about whether Amarin Corporation plc or CRISPR Therapeutics AG is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.